Swiss biotech saw record revenues in 2025, report says
The Swiss biotech industry recorded its highest ever revenues in 2025, a new report shows.
The 2026 Swiss Biotech Report says the industry saw record revenues of CHF 7.5 billion (€8.2 billion) in 2025, up from CHF 7.2 billion (€7.9 billion) in 2024.
Employment in Swiss R&D biotech companies also reached a record of more than 21,000 FTEs, suggesting companies are advancing into the commercial stage and the importance of Swiss CDMO is increasing.
Elsewhere, privately funded companies raised a record CHF 1.15 billion (€1.26 billion), up 38% from 2024. Private financing in 2025 accounted for 45% of total funding, compared to around 30% in prior years.
Although public companies battled market challenges, Swiss pharmaceutical company BioVersys completed Europe’s largest IPO in early 2025, raising $88 million (compared to $106 million raised by four European IPOs in 2024).
“The strong performance of the industry in 2025 is welcome testimony to our commitment to nurturing talent, fostering innovation and promoting international collaboration,” said Michael Altorfer, CEO, Swiss Biotech Association.
“Most investment continues to come from abroad and, in USD, is growing at 20% year on year — an impressive achievement in the current economic and political climate.”
